Glen Eagle Advisors’s Exact Sciences EXAS Stock Holding History

Glen Eagle Advisors’s Portfolio EXAS Stock Details EXAS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-26	Closed	-$1.1K	–	1170
2024 Q2	$1.1K	Buy	+26	New	+$1.43K	﹤0.01%	985

Other funds holding EXAS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Glen Eagle Advisors's EXAS Position: Q3 2024 in Review

Glen Eagle Advisors sold out of Exact Sciences (EXAS) in Q3 2024, closing a stake of 26 shares — an estimated $1.1K sold.

Glen Eagle Advisors first reported a position in EXAS in Q2 2024 and held it in 1 quarter. The position peaked at $1.1K in Q2 2024. 598 funds tracked by Wall St. Rank hold EXAS as of Q3 2024.

Glen Eagle Advisors reported no remaining Exact Sciences position as of Q3 2024 after selling out during the quarter.
Glen Eagle Advisors sold 26 Exact Sciences shares in Q3 2024, an estimated $1.1K.
Glen Eagle Advisors first reported a position in Exact Sciences in Q2 2024 and held it in 1 quarter.
Glen Eagle Advisors's Exact Sciences position peaked at $1.1K in Q2 2024.
598 funds tracked by Wall St. Rank held Exact Sciences as of Q3 2024.

Based on Glen Eagle Advisors's 13F filing for Q3 2024, filed 15 Nov 2024.